KALA BIO, Inc.

DB:27F0 Stock Report

Market Cap: €26.2m

KALA BIO Management

Management criteria checks 2/4

KALA BIO's CEO is Mark Iwicki, appointed in Sep 2015, has a tenure of 9.25 years. total yearly compensation is $8.34M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 1.57% of the company’s shares, worth €412.14K. The average tenure of the management team and the board of directors is 6.6 years and 7.3 years respectively.

Key information

Mark Iwicki

Chief executive officer

US$8.3m

Total compensation

CEO salary percentage8.5%
CEO tenure9.3yrs
CEO ownership1.6%
Management average tenure6.6yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mark Iwicki's remuneration changed compared to KALA BIO's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$39m

Jun 30 2024n/an/a

-US$39m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$8mUS$709k

-US$42m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$9m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$2mUS$682k

-US$45m

Sep 30 2022n/an/a

-US$80m

Jun 30 2022n/an/a

-US$137m

Mar 31 2022n/an/a

-US$145m

Dec 31 2021US$3mUS$644k

-US$143m

Sep 30 2021n/an/a

-US$126m

Jun 30 2021n/an/a

-US$126m

Mar 31 2021n/an/a

-US$113m

Dec 31 2020US$5mUS$586k

-US$104m

Sep 30 2020n/an/a

-US$95m

Jun 30 2020n/an/a

-US$90m

Mar 31 2020n/an/a

-US$91m

Dec 31 2019US$3mUS$564k

-US$94m

Sep 30 2019n/an/a

-US$98m

Jun 30 2019n/an/a

-US$90m

Mar 31 2019n/an/a

-US$81m

Dec 31 2018US$3mUS$535k

-US$67m

Sep 30 2018n/an/a

-US$53m

Jun 30 2018n/an/a

-US$47m

Mar 31 2018n/an/a

-US$44m

Dec 31 2017US$2mUS$501k

-US$42m

Compensation vs Market: Mark's total compensation ($USD8.34M) is above average for companies of similar size in the German market ($USD469.36K).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.

CEO

Mark Iwicki (58 yo)

9.3yrs

Tenure

US$8,342,714

Compensation

Mr. Mark T. Iwicki has been Director at Q32 Bio Inc since March 2023. Mr. Iwicki previously served as the Chairman of Legacy Q32’s board of directors since 2020. He had been Chairman of Aerovate Therapeuti...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Iwicki
Chairman & CEO9.3yrsUS$8.34m1.57%
€ 412.1k
Todd Bazemore
President & COO7.1yrsUS$2.94m0.49%
€ 127.3k
R. Brazzell
Head of R&D and Chief Medical Officer11.8yrsUS$2.92m0.54%
€ 140.4k
Justin Hanes
Founder & Chair of the Scientific Advisory Boardno datano datano data
Mary Reumuth
CFO & Treasurer10.8yrsno data0.35%
€ 91.3k
Jill Steier
Executive Director of Investor Relations & Corporate Communications3.4yrsno datano data
Vincent Kosewski
Senior VP of Manufacturing & Supply Chain Management7.4yrsno datano data
Darius Kharabi
Chief Business Officer3.1yrsno data0.48%
€ 126.0k
Francis Mah
Chief Medical Advisor1.8yrsno datano data
Josiah Craver
Senior VP & Corporate Controller2.7yrsno datano data
Carl Rennie
Executive Director of Account Management6.6yrsno datano data
Patrick Bedell
Executive Director of Trade & Alternate Channels6.6yrsno datano data

6.6yrs

Average Tenure

56yo

Average Age

Experienced Management: 27F0's management team is seasoned and experienced (6.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Iwicki
Chairman & CEO9.7yrsUS$8.34m1.57%
€ 412.1k
Justin Hanes
Founder & Chair of the Scientific Advisory Boardno datano datano data
Jonathan Silverstein
Board Observer8.7yrsno datano data
Gregory Perry
Independent Director6.8yrsUS$302.01k0.051%
€ 13.5k
Peter Hutt
Member of Scientific Advisory Boardno datano datano data
Andrew Koven
Lead Independent Director7.3yrsUS$402.36k0.066%
€ 17.4k
Ronald Krall
Member of Scientific Advisory Boardno datano datano data
Bennett Shapiro
Member of Scientific Advisory Boardno datano datano data
Colin Gardner
Member of Scientific Advisory Boardno datano datano data
Charles Myers
Independent Director3.2yrsUS$236.94k0.029%
€ 7.5k
Howard Rosen
Independent Director & Member of Advisory Board10.9yrsUS$392.20k0.065%
€ 17.1k
Marjan Farid
Independent Director2.2yrsUS$225.64k0.024%
€ 6.3k

7.3yrs

Average Tenure

66yo

Average Age

Experienced Board: 27F0's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:37
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

KALA BIO, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Yi ChenH.C. Wainwright & Co.
Raghuram SelvarajuH.C. Wainwright & Co.